Skip to content
Resources > Reports

Navigating Biopharma Policy: 2025 Changes and a Look Ahead

By Sara Mallatt, Director of Healthcare Research and Sean Carmichael
IndustryLife Sciences & Healthcare

Biopharma firms are grappling with a turbulent and complex policy landscape. The threat of 100% tariffs on imported branded drugs have fundamentally altered business strategy for firms, spurring dealmaking with the federal government in exchange for tariff relief. Heightened policy uncertainty is forcing manufacturers to reevaluate pricing and go-to-market strategies, with a severe expected revenue impact.

AlphaSense recently hosted a webinar with Dr. Robert Popovian, Chief Science Policy Officer at the Global Health Living Foundation to discuss these issues and more. This report leverages key insights from Dr. Popovian and those available in AlphaSense to explore the key policy shifts shaping the biopharma ecosystem.

About the Authors
  • Sara Mallatt

    Sara Mallatt, Director of Healthcare Research

    Sara has more than 18 years of experience generating sell-side research content across a variety of industries. Prior to joining AlphaSense, Sara held leadership positions at OTR Global, a leading channel research firm, most recently as Director of Healthcare Research. Sara holds a bachelor’s degree in journalism and a master’s in industrial engineering. She works from her home in Missoula, Montana.
  • Sean Carmichael

    Sean Carmichael

    Sean is a Business & Finance Editor at AlphaSense, specializing in sector-specific content production. Previously, he spent nearly a decade in various roles across financial services, where he was responsible for equity research and content generation geared toward institutional investors.

Explore more

All articles

Top AI Use Cases for Investment Firms

Recent findings show that while financial services companies are rapidly scaling enterprise AI integration, a majority are still not generating meaningful ROI.
ReportFinancial Services
Title: Top AI Use Cases for Investment Firms in 2026 by Barb Togue, illustrated with outline icons of money, circulation, and a magnifying glass.

Top AI Use Cases for Consulting Firms

The top consulting teams have moved beyond isolated AI experimentation and disconnected tools. They’re using AI to generate decision-grade outputs tailored specifically to them. In this report, learn the top AI use cases that are transforming how consulting teams operate.
ReportConsulting
Title: Top AI Use Cases for Consulting Firms, with isometric line art illustrations of a data dashboard, chat bubbles, and a person working at multiple monitors.

Luxury at an Inflection Point: What the Numbers Aren’t Telling Investors

Luxury has enjoyed close to four decades of near-continuous growth, and the industry has come to view that run as a baseline rather than an exception.
ReportConsumer/CPGFinancial Services
Dark blue graphic with the title "Luxury at an Inflection Point: What the Numbers Aren't Telling Investors." Features blue line drawings of a watch, handbag, and high heels, with text mentioning interviews with LVMH and Prada executives.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.